Pfizer Inc., Bristol-Myers Squibb Company, and Novartis AG dominated the Ecuador Acute Myeloid Leukemia Drugs Market in 2021

Ecuador Acute Myeloid Leukemia Drugs Market is expected to grow with the CAGR of 4.5% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/ecuador-acute-myeloid-leukemia-drugs-market

Ecuador acute myeloid leukemia drugs market is a highly consolidated market. The market has witnessed increased strategic developments owing to favorable market scenarios.

Some of the major players dealing in the acute myeloid leukemia market are introducing strong range of product portfolios. This helped companies to maximize sales with enhanced product portfolio.

Pfizer Inc., is dominating player in the Ecuador acute myeloid leukemia drugs market. The other key players existing in the market includes are Bristol-Myers Squibb Company, Novartis AG, AbbVie Inc., Merck Sharpe and Dohme, F. Hoffmann-La Roche Ltd, FRESENIUS KABI AG and Others.

Pfizer Inc.

Pfizer Inc. was founded in 1849 and is headquartered in New York, U.S. The company focuses on providing quality standards, safety and value in the discovery, development and manufacturing of healthcare products, including innovative medicines and vaccines. The company offers range of product categories including Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease, Vaccines, and Anti Infectives in which market focused category fall under oncology. The company is taking strategic initiatives by collaboration.

The company has global presence in North America, Europe, Middle East and Africa, Asia-Pacific and South America and Pfizer Animal Health B.V. (Netherlands), Pfizer Asia International B.V. (Netherlands), Pfizer Australia Superannuation Pty Ltd (Australia), Pfizer Dominicana, S.A. (Dominican Republic) and Pfizer Egypt S.A.E. (Egypt), among others among others are the subsidiary of Merck KGaA.

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, U.S. The company focuses on innovating new solutions in oncology, hematology, immunology and cardiovascular disease by accelerating advancing treatments and improving patients’ therapies. The company offers range of product categories Solid tumors, Hematology, Cardiovascular, Immunology, Fibrotic Diseases, Neuroscience, Translational medicine, Digital health, Cell therapy and Research technologies and our market focused category is immunology and hematology. The company is taking strategic initiatives to increase its product portfolio.

  • In June 2021, Bristol Myers Squibb had received approval from European Commission for Onureg. Onureg is used as a Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia. The approval received would ensure post marketing approval in the U.S., Europe and South America region. Onureg is expected to increase the sales and product revenue in Ecuador and Peru, thereby increasing the market growth

The company has global presence in North America, Asia Pacific, South America, Europe, and Latin America. The company has many subsidiaries such as BMS Pharmaceuticals Germany Holdings B.V., BMS Pharmaceuticals International Holdings Netherlands B.V., BMS Pharmaceuticals Korea Holdings B.V., BMS Pharmaceuticals Mexico Holdings B.V., BMS Pharmaceuticals Netherlands Holdings B.V., among others.

Novartis AG

Novartis AG was founded in 1996 and is headquartered in Baden-Württemberg, Switzerland. The company focuses on innovating new solutions for various healthcare challenges. The company offers products in following categories Cancer, Cardiovascular, Renal & Metabolism, Immunology & Dermatology, Ophthalmology, Neuroscience, Respiratory and innovative medicines is the market focused category from which our market focused category is innovative medicines and cancer. The company is taking strategic initiatives to increase its product portfolio.

  • In September 2017, Novartis Ag, had received approval from the European Union, for Rydapt for treatment of FLT3-mutated acute myeloid leukemia (AML). The approval received would ensure post marketing approval of Rydapt in Europe and in countries in South America. The approval received was based on data from largest landmark trials, in acute myeloid leukemia

The company has global presence in North America, Europe, South America, Middle East and Africa, Asia-Pacific. The company has many subsidiaries such as Novartis Argentina S.A., Buenos Aires (Argentina), Novartis Australia Pty Ltd, Macquarie Park, NSW (Australia), Novartis Austria GmbH, Vienna (Austria), Novartis Pharma NV, Vilvoorde (Belgium), among others.